Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.
Bohl S, von Harsdorf S, Mulaw M, Hofmann S, Babiak A, Maier CP, Schnell J, Hütter-Krönke LM, Scholl K, Wais V, Schlenk RF, Bullinger L, Ringhoffer M, Döhner H, Bunjes D, Bommer M, Kuchenbauer F.
Bohl S, et al. Among authors: von harsdorf s.
Bone Marrow Transplant. 2016 Jul;51(7):994-6. doi: 10.1038/bmt.2016.4. Epub 2016 Mar 7.
Bone Marrow Transplant. 2016.
PMID: 26950380
Free PMC article.
No abstract available.